EPIDEMIOLOGY INFORMATION RESOURCE ON OPTICAL DISC

癌症研究是全世界范围内的一项重要活动 许多人都在忙碌；这是非常有活力的，而且有很多是 每年陪伴一次。这项研究的信息支持至关重要 分享成果和研究结果，避免重复劳动等。 该项目的目标是提供全面的癌症信息 支持全球癌症研究的资源(CIR)使用廉价的 个人计算机(PC)和光盘技术。在成功的 在第一阶段活动中，开发了一个完全可操作的原型系统， 其中包括国际癌症研究机构(IARC) 《1989/90年癌症流行病学正在进行的研究目录》光盘- 可在PC上操作的ROM(光盘只读存储器)光盘 拥有强大的信息检索软件。在第二阶段，我们将 从原型开始，到准备好商业化的产品。 CIR产品将包含超过50倍的体积 以信息为原型，都与癌症研究和 将流行病学与其他研究领域联系起来(根据 DBIR应用程序包，我们保留了第一阶段的标题 工作，但CIR产品的内容范围将比 原型的版本)。此外，该软件将大大提高 增强以提供所有数据库之间的超文本链接，以便 该产品将完全集成在一起，非常易于使用。测试版 将在第三世界国家进行测试，并在#年末 在第二阶段，该产品将准备好进行商业分发 世界各地的癌症研究人员。

Cancer research is an important activity throughout the world in which many persons are engaged; it is extremely dynamic and much is accompanied annually. Information support for this research is critical to share results and findings, to avoid duplication of effort, etc. The goal of this project is to provide a comprehensive Cancer Information Resource (CIR) to support worldwide cancer research using inexpensive Personal Computer (PC) and optical disc technologies. In the successful Phase I activity, a fully operational prototype system was developed, which contained the International Agency for Research on Cancer (IARC) Directory of On-Going Research in Cancer Epidemiology 1989/90 on a CD- ROM (Compact Disc - Read Only Memory) optical disc, operable on a PC with powerful information retrieval software. In Phase II we will proceed from that prototype to a product ready for commercialization. The CIR product will contain more than 50 times as much volume of information as the prototype, all related to cancer research and relating epidemiology to other research areas (per the instructions of the DBIR application package, we have retained the title of the Phase I work, but the content of the CIR product will be broader in scope than that of the prototype). In addition, the software will be greatly enhanced to provide hypertext linkages among all the databases so that the product will be fully integrated and extremely easy to use. Beta testing in third-world countries will be conducted, and at the end of this Phase II the product will be ready for commercial distribution to cancer researchers throughout the world.